- Home
- FATE vs YMAB Comparison
FATE vs YMAB Comparison
Compare FATE & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- YMAB
- Stock Information
- Founded
- FATE 2007
- YMAB 2015
- Country
- FATE United States
- YMAB United States
- Employees
- FATE N/A
- YMAB N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- YMAB Health Care
- Exchange
- FATE Nasdaq
- YMAB Nasdaq
- Market Cap
- FATE 177.7M
- YMAB 192.4M
- IPO Year
- FATE 2013
- YMAB 2018
- Fundamental
- Price
- FATE $1.14
- YMAB $4.36
- Analyst Decision
- FATE Hold
- YMAB Buy
- Analyst Count
- FATE 7
- YMAB 11
- Target Price
- FATE $3.83
- YMAB $17.55
- AVG Volume (30 Days)
- FATE 1.9M
- YMAB 202.0K
- Earning Date
- FATE 08-12-2025
- YMAB 08-11-2025
- Dividend Yield
- FATE N/A
- YMAB N/A
- EPS Growth
- FATE N/A
- YMAB N/A
- EPS
- FATE N/A
- YMAB N/A
- Revenue
- FATE $13,335,000.00
- YMAB $88,658,000.00
- Revenue This Year
- FATE N/A
- YMAB N/A
- Revenue Next Year
- FATE N/A
- YMAB $15.15
- P/E Ratio
- FATE N/A
- YMAB N/A
- Revenue Growth
- FATE 105.85
- YMAB 4.92
- 52 Week Low
- FATE $0.66
- YMAB $3.55
- 52 Week High
- FATE $5.92
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- FATE 46.69
- YMAB 45.29
- Support Level
- FATE $1.05
- YMAB $4.10
- Resistance Level
- FATE $1.18
- YMAB $4.62
- Average True Range (ATR)
- FATE 0.08
- YMAB 0.29
- MACD
- FATE -0.00
- YMAB -0.04
- Stochastic Oscillator
- FATE 54.76
- YMAB 20.73
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.